Non-anemic iron deficiency in copd morbidity

Active Grant Awarded

Award ID
K23HL181396
Recipient
Awarding agency
Obligated
$196,020

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 4% complete
Place of performance
Baltimore, MD 21205, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute awarded The Johns Hopkins University $196,020 on September 9, 2026. The award is a grant under Cardiovascular Diseases Research (CFDA 93.837) and funds Grant K23HL181396, a study of non-anemic iron deficiency in chronic obstructive pulmonary disease (COPD). The project will determine whether non-anemic iron deficiency, measured by transferrin saturation as iron availability, is a determinant of COPD outcomes and will identify the target population for iron repletion. The work proceeds in three parts: an ancillary study of subpopulations and intermediate outcome measures in the NIH-funded SPIROMICS multi-center longitudinal cohort, to define the association between non-anemic iron deficiency and COPD-specific outcomes; an investigation within SPIROMICS of iron sequestration and COPD exacerbation risk; and a local observational cohort of individuals with moderate to severe COPD undergoing pulmonary rehabilitation, to assess how iron availability relates to gains in exercise capacity. Place of performance is Baltimore, Maryland 21205. The period of performance runs from the award date to an ultimate completion date of August 31, 2031.

Description

Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, often accompanied by comorbid diseases that may serve as treatable targets to improve COPD outcomes. Iron deficiency is one such modifiable and widely prevalent comorbidity with existing, affordable therapies. Iron is essential for biologic processes highly relevant to COPD which can be altered in iron deficient states even in the absence of anemia. While there have been small studies of iron deficiency in COPD, non-anemic iron deficiency (NAID) as an independent entity has not been investigated. Furthermore, prior studies have relied on ferritin to define iron deficiency which is now recognized to have limitations in chronic disease states and multimorbidity. Instead, there is interest in iron availability measured by transferrin saturation (TSAT), which can be reduced due to low total body iron or iron sequestration, to study iron deficiency in chronic diseases such as COPD. The main objective of this proposal is to understand whether NAID measured by iron availability is a determinant of COPD outcomes and to identify the target population for treatment with iron repletion. First, we propose an ancillary study of the subpopulations and intermediate outcome measures in COPD study (SPIROMICS), an NIH-funded multi-center longitudinal cohort to more definitively determine the association between NAID and COPD specific outcomes. To understand the COPD subpopulation in whom iron repletion may pose risk, we will also investigate iron sequestration, an etiology of low iron availability, and COPD exacerbation risk within SPIROMICS. Finally, we will build a local observational cohort study of individuals with moderate to severe COPD undergoing pulmonary rehabilitation, an evidenced based COPD intervention for exercise intolerance, to assess how iron availability is associated with gains in exercise capacity. As iron is essential for cellular respiration and exercise capacity is an important predictor of COPD morbidity, individuals undergoing pulmonary rehabilitation may especially stand to benefit from treatment of NAID. Completion of the proposed aims will elucidate the impact of NAID on COPD outcomes including responsiveness to pulmonary rehabilitation, clinical utility of iron availability (TSAT) as a measure of iron deficiency, and whether level of iron sequestration measured by biomarker hepcidin can identify individuals at higher risk of adverse effects of iron repletion. Study results will provide rationale for and inform the design of a future clinical trial of iron repletion for NAID in COPD. Lastly, this proposal will also serve as an important vehicle for clinical research training and career development, comprised of expert mentorship, hands-on experience, and coursework to build skills in design, conduct and analysis of clinical studies, and expertise in physiologic measures of COPD outcomes as well as iron biology. This will support my ultimate career goal to be an independent clinical investigator at the cross-disciplinary intersection of COPD and comorbid diseases to identify and assess novel therapeutic interventions to reduce the global COPD burden.

Quick answers

Who received award K23HL181396?

K23HL181396 was awarded to The Johns Hopkins University by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.

How much is award K23HL181396 worth?

$196,020 has been obligated on K23HL181396.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award